Ethyl pyruvate stabilizes hypoxia-inducible factor 1 alpha via stimulation of the TCA cycle

Cancer Letters

Volumn 295, Issue 2, 2010, Pages 236-241

  Kim, Seon Ye ^a   Choi, Jae Sun ^a   Park, Chan ^a   Jeong, Joo Won ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Ethyl pyruvate; HIF 1 ; ROS; TCA cycle

Indexed keywords

CITRIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PYRUVIC ACID DERIVATIVE; PYRUVIC ACID ETHYL ESTER; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; REGULATORY MECHANISM;

CELL LINE, TUMOR; CITRIC ACID CYCLE; HEP G2 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOCHONDRIA; PYRUVATES; REACTIVE OXYGEN SPECIES; UBIQUITINATION;

EID: 77954033751     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.03.006     Document Type: Article

References (29)

1. Gordan J.D., Simon M.C. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr. Opin. Genet. Dev. 2007, 17:71-77.
2. 2 sensing. Science 2001, 292:464-468.
3. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
4. Dery M.A., Michaud M.D., Richard D.E. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int. J. Biochem. Cell Biol. 2005, 37:535-540.
5. Lu H., Forbes R.A., Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 2002, 277:23111-23115.
6. Ganapathy V., Thangaraju M., Prasad P.D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 2009, 121:29-40.
7. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
8. Gatenby R.A., Gawlinski E.T. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003, 63:3847-3854.
9. Fink M.P. Ethyl pyruvate: a novel anti-inflammatory agent. J. Intern. Med. 2007, 261:349-362.
10. Zeng J., Liu J., Yang G.Y., Kelly M.J., James T.L., Litt L. Exogenous ethyl pyruvate versus pyruvate during metabolic recovery after oxidative stress in neonatal rat cerebrocortical slices. Anesthesiology 2007, 107:630-640.
11. Sappington P.L., Han X., Yang R., Delude R.L., Fink M.P. Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated caco-2 enterocytic monolayers. J. Pharmacol. Exp. Ther. 2003, 304:464-476.
12. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002, 111:709-720.
13. Bae M.K., Jeong J.W., Kim S.H., Kim S.Y., Kang H.J., Kim D.M., Bae S.K., Yun I., Trentin G.A., Rozakis-Adcock M., Kim K.W. Tid-1 interacts with the von Hippel-Lindau protein and modulates angiogenesis by destabilization of HIF-1alpha. Cancer Res. 2005, 65:2520-2525.
14. Ehrhanrdt C., Schmolke M., Matzke A., Knoblauch A., Will C., Wixler V., Ludwing S. Polyethylenimine, a cost-effective transfection reagent. Signal Transduction 2006, 6:179-184.
15. Ahn K.H., Kim Y.S., Kim S.Y., Huh Y., Park C., Jeong J.W. Okadaic acid protects human neuroblastoma SH-SY5Y cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis. Neurosci. Lett. 2009, 449:93-97.
16. Arnold S., Kadenbach B. Cell respiration is controlled by ATP, an allosteric inhibitor of cytochrome-c oxidase. Eur. J. Biochem. 1997, 249:350-354.
17. Yeung S.J., Pan J., Lee M.H. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol. Life Sci. 2008, 65:3981-3999.
18. Lee M.S., Moon E.J., Lee S.W., Kim M.S., Kim K.W., Kim Y.J. Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. Cancer Res. 2001, 61:3290-3293.
19. Lu H., Dalgard C.L., Mohyeldin A., McFate T., Tait A.S., Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J. Biol. Chem. 2005, 280:41928-41939.
20. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5:343-354.
21. Min J.H., Yang H., Ivan M., Gertler F., Kaelin W.G., Pavletich N.P. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 2002, 296:1886-1889.
22. Galanis A., Pappa A., Giannakakis A., Lanitis E., Dangaj D., Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett. 2008, 266:12-20.
23. Hervouet E., Cizkova A., Demont J., Vojtiskova A., Pecina P., Franssen-van Hal N.L., Keijer J., Simonnet H., Ivanek R., Kmoch S., Godinot C., Houstek J. HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis 2008, 29:1528-1537.
24. Fink M.P. Ethyl pyruvate: a novel treatment for sepsis and shock. Minerva Anestesiol. 2004, 70:365-371.
25. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic and molecular aspects. J. Natl. Cancer Inst. 2001, 93:266-276.
26. Zhang Y., Li M., Meng M., Qin C. Effect of ethyl pyruvate on physical and immunological barriers of the small intestine in a rat model of sepsis. J. Trauma 2009, 66:1355-1364.
27. Yu Y.M., Kim J.B., Lee K.W., Kim S.Y., Han P.L., Lee J.K. Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke; J. Cerebr. Circulation 2005, 36:2238-2243.
28. Liang X., Chavez A.R., Schapiro N.E., Loughran P., Thorne S.H., Amoscato A.A., Zeh H.J., Beer-Stolz D., Lotze M.T., de Vera M.E. Ethyl pyruvate administration inhibits hepatic tumor growth. J. Leukoc. Biol. 2009, 86:599-607.
29. Fink M.P. Ethyl pyruvate. Curr. Opin. Anaesthesiol. 2008, 21:160-167.